research Peer-reviewed study October 2, 2026 via International journal of molecular medicine

miR‑222‑3p inhibits diabetic skin wound healing by targeting APLN

Diabetic foot ulcers are slow-healing wounds that can lead to amputation, so understanding why healing stalls matters to patients and families. This study looked at a tiny molecule called miR-222-3p, which helps regulate how cells behave, and at a protein called APLN (apelin) that supports blood vessel growth. Researchers tested human skin blood-vessel cells in the lab and also used diabetic mice to see how these molecules affect wound healing. They found that a sugar-related substance common in diabetes raised miR-222-3p, which in turn reduced APLN and made blood vessel cells grow and migrate less well and die more. In living mice, boosting miR-222-3p slowed wound healing and lowered APLN in the skin around the wound. But when the researchers either supplied the apelin protein or blocked miR-222-3p, wound healing improved again. These findings are early-stage and come from cells and mice, not from people, so they point to a possible future treatment target rather than an available therapy. Patients should not change their care based on animal studies, but this work adds to understanding of why diabetic wounds heal poorly.

Medically reviewed by Professor Cheng Wang, MD

Key takeaways

  • Diabetic foot ulcers heal slowly partly because blood vessel cells in the skin function poorly and fail to form new vessels.
  • In lab and mouse experiments, higher levels of miR-222-3p reduced a growth-supporting protein called apelin and impaired healing.
  • Blocking miR-222-3p or adding apelin restored healing in mice, suggesting a possible future treatment target.
  • The study used human cells in a dish and diabetic mice, so results have not yet been tested in patients.
  • Ask your doctor whether your wound care includes checking blood flow to the foot and controlling blood sugar closely.
  • Do not stop or change any foot ulcer treatment based on this early research; discuss new findings with your care team.

Editor's note

Think of a diabetic wound as a town whose water supply is getting cut off: small blood vessels are the pipes that deliver oxygen and repair materials, and miR-222-3p acts like a valve that narrows those pipes by switching off a protective protein called apelin. In mice, reopening that valve, either by blocking miR-222-3p or by supplying apelin, helped the wound heal. If you have been told your ulcer will not heal or that amputation is the only option, this is genuinely hopeful science, but it is still mouse-and-cell research, not a treatment you can receive today. At China's specialist DFU centres, standard care already includes removing dead tissue, offloading pressure, controlling blood sugar, and treating infection and blood flow, and this type of molecular therapy is not routinely offered; for an overseas patient, that means the realistic choice now is a comprehensive wound-care evaluation, with this research as a reason to keep asking about new options as they develop.

This content summarizes published medical research for educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making treatment decisions.

Free consultation

Could this treatment help you?

Our DFU specialists review every inquiry personally. Tell us about your situation — response within 48 hours, no commitment required.

This website provides medical-information science popularization only. It does NOT provide online diagnosis, prescriptions, or medical advice. Consult a licensed physician for any medical decision.

How we can reach you
Please do NOT enter detailed medical information.

← All news